CROI 2019 Program and Conference Information

Oral Sessions

Preconference Session • Monday 2:00 PM - 4:00 PM Target Audience: This session is directed to clinicians and scientists who are interested in designing or interpreting clinical and epidemiologic studies. Level of Knowledge: It is assumed that participants are familiar with the basic design of randomized and observational clinical trials and with basic HIV epidemiology. Objectives: After attending this session, learners will be able to: • Describe microbiomic data • Identify howmissing data can be managed • Appreciate novel methods for evaluating and interpreting HIV prevention trials Conveners Richard E. Chaisson, Johns Hopkins University, Baltimore, MD, USA Susan P. Buchbinder, San Francisco Department of Public Health, San Francisco, CA, USA 6 FELLOWTRAVELERS: INTERPRETING THE IMPACT OF THEMICROBIOME IN CLINICAL INTERVENTION Adam Burgener, Public Health Agency of Canada, Winnipeg, MB, Canada 7 MISSING U: HANDLING AND AVOIDINGMISSING DATA IN CLINICAL TRIALS Heather Ribaudo, Harvard T.H. Chan School of Public Health, Boston, MA, USA 8 DESIGNING& INTERPRETING HIV PREVENTION TRIALS IN THE ERA OF EFFECTIVE INTERVENTIONS David Dunn, University College London, London, UK WorkshopW-3 CLINICAL TRIAL DESIGN AND ANALYSIS Room 6C WorkshopW-4 INTERACTIVE CASE-BASEDWORKSHOP ON HEPATITIS Room 6E 2:00 PM - 4:00 PM Target Audience: This session is directed to persons interested in the management of hepatitis C, D, or E viral infections as well as management of NASH. Level of Knowledge: It is assumed that participants are familiar with the general principles of hepatitis treatment and the medications used as well as the basics of fatty liver disease. Objectives: At the completion of the session, participants will be able to: • Diagnose and manage liver disease in HIV coinfection including NASH, hepatitis C, D, and E, and taking care of advanced liver disease stages CME CME

CROI 2019 28